Novartis (SWX:NOVN) Stock Faces Flat Margins As Q2 Net Profitability Narrative Is Tested

Novartis (SWX:NOVN) has posted fresh Q2 2026 numbers, with revenue at US$14.9 billion, basic EPS of US$1.71 and net income of US$3.3 billion, giving investors a clear read on how the business is currently earning its profits. Over recent quarters the company has seen revenue move between US$13.5 billion and US$14.9 billion, while basic EPS has ranged from US$1.26 to US$2.07. This provides a consistent earnings backdrop for assessing the latest release. With a trailing net profit margin of 23.9% and earnings forecasts in place, the focus now shifts to how sustainable this profitability profile looks from here.

See our full analysis for Novartis.

With the headline numbers on the table, the next step is to see how these results line up against the main stories investors already have about Novartis and where those narratives might need an update.

See what the community is saying about Novartis

Margins Hold Near 24% As Growth Mix Shifts

• On a trailing basis, Novartis is earning US$12.8b of net income on US$56.7b of revenue, which works out to a 23.9% net profit margin compared with 24.2% a year ago.
• Bulls point to strong demand for higher value therapies as a support for margins, yet the slight margin slip tests that view:
  • Consensus narrative highlights double digit sales growth in brands like Kisqali, Kesimpta, Scemblix and Pluvicto, which is cited as a support for long term margin expansion. However, the current 23.9% margin shows that newer launches, generic pressure and investment are still keeping profitability close to flat year on year.
  • Bullish commentary also talks about operational efficiency and portfolio streamlining helping margins over time, while the modest move from 24.2% to 23.9% indicates those efficiency gains are so far only offsetting other cost and pricing headwinds rather than clearly lifting profitability.

Novartis bulls argue that these Q2 figures sit at the start of a much stronger margin story, so it is worth checking how that thesis lines up with the detailed narrative in 🐂 Novartis Bull Case.

5.2% One Year Earnings Growth Versus Five Year Drag

• Over the last year, earnings grew 5.2% against a five year trend where earnings declined 2.7% per year, which means the current US$12.8b of trailing net income is running ahead of that longer term pattern.
• Bears focus on longer term pressure on profits, and the numbers leave a mixed picture for that cautious stance:
  • Bears highlight upcoming and ongoing generic erosion for legacy products like Entresto, Tasigna and Promacta as a reason earnings progress could stall, and the five year decline of 2.7% per year gives that concern some backing even though the latest 5.2% growth shows recent results are holding up better than that historic drag.
  • Critics also point to heavy spending on late stage programs and deals such as Avidity as a potential cap on profit growth, with the current US$12.8b of net income needing to stretch across both those investments and a high level of debt. This supports the idea that any setback in the pipeline could quickly show up in this still modest one year growth rate.

Skeptics who see this five year earnings pattern as a warning flag may want to compare their view with how the more cautious narrative frames future profit potential in 🐻 Novartis Bear Case.

DCF Fair Value of 309.28 Versus 21x P/E Today

• With the share price at CHF125.54, Novartis trades on a P/E of about 21x, roughly in line with the European pharmaceuticals industry at 21.1x, and far below a DCF fair value of CHF309.28 that sits well above the current market level.
• Consensus narrative leans on this valuation gap as a support for the stock, and the Q2 profile gives several concrete checks against that idea:
  • Analysts are assuming earnings growth of about 9.7% per year and revenue growth of about 5% per year from a base of US$56.7b of trailing revenue and US$12.8b of net income. This is the growth path that would need to justify both the DCF fair value of CHF309.28 and an analyst target of CHF123.68 relative to the current CHF125.54 share price.
  • At the same time, Novartis carries a 2.93% dividend yield and a high level of debt, so the current 21x P/E and the large gap to the DCF fair value are effectively asking investors to weigh steady profitability and income against balance sheet risk and a five year earnings trend that has declined 2.7% per year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Novartis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed signals across Novartis earnings, margins and valuation, it is worth checking the numbers yourself and deciding how much risk and reward you are comfortable with, starting with the balance of 4 key rewards and 1 important warning sign.

See What Else Is Out There Beyond Novartis

Novartis is running with a flat to slightly softer margin profile, a five year earnings drag and a higher debt load that keeps some investors cautious.

If you want stocks where profitability trends and balance sheets look more resilient right now, it is worth running a quick check through the 293 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com